Rehabilitation Study in MS Patients

Multiple Sclerosis, Relapsing-Remitting Clinical Trial

Official title:

Multicenter, Open Label, Randomized and Parallel Group Phase IV Pilot Study Evaluating the Effectiveness of Functional Rehabilitation Protocol in RRMS Patients Treated With Betaferon®

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00780455
• Other study ID #: 13089
• Secondary ID: 2006-006673-2430
• Status: Terminated
• Phase: Phase 4
• First received: May 28, 2008
• Last updated: May 8, 2015
• Start date: October 2008
• Est. completion date: September 2009

Study information

• Verified date: May 2015
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

Studying the effectiveness of a functional rehabilitation protocol (FRP) in early Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with Betaferon by comparing the physical ability of patients with and without FRP.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: September 2009
• Est. primary completion date: September 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Female and Male patients aged 18 and more;

• Confirmed diagnosis of RRMS according to the MacDonald or Poser criteria;

• First indication for Betaferon treatment (as described in Summary of Product Characteristics (SmPC));

• No relapse of multiple sclerosis (MS) in the last two months before the inclusion;

• Walking patients having an Expanded Disability Status Scale (EDSS) score between > 1 and </= 4 at the inclusion visit;

• Female of child-bearing potential must agree to practice adequate contraception methods over all the duration of the study;

• Patient can follow all the study and comply with all procedures of the trial protocol

• Laboratory evaluations (i.e. evaluation of hepatic enzymes gammaGT, full blood count and differential white blood cell [WBC]) must be available and the results must be normal;

• Written informed consent.

Exclusion Criteria:

• Any contraindication to Betaferon as described in the SmPC of the product;

• Patient with a previously orthopaedic surgical intervention within the past year of the inclusion;

• Patient previously included in this study;

• Patient previously treated within the past 3 months with Rebif, Avonex or Copaxone;

• Patient previously treated within the past 12 months with Betaferon;

• Participation in any clinical trial within the past 30 days involving the investigational drug intake.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Relapsing-Remitting

Intervention

Drug:
• Interferon beta-1b, FRP within 15 days after randomization
Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program starting within 6 weeks after randomization
• Interferon beta-1b, FRP about 6 weeks after randomization
Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program about 6 weeks after randomization.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total Walking Area (in Covered Meters) Either After 6 Minute or at the Time of the Premature Stop of the Test.		Up to 6 minutes	No
Primary	Time of Discomfort Appearance		Up to 6 minutes	No
Primary	Distance of Discomfort Appearance		Up to 6 minutes	No
Primary	Rhythm Change During 6 Minutes Walking Test		Up to 6 minutes	No
Secondary	Covered Distance Gain Between MR2 Visit and MR3 Visit	Participants had the following two types of visit during the study, one visit with a neurologist and one visit with a rehabilitation physician. Visit to a neurologist: V0=baseline; V1=end of Month 1 of treatment; V2=end of Month 2 of treatment; V3=end of Month 3 of treatment. Visit to MR (Medecin Reeducateur: physician for rehabilitation): MR1=1st visit within 15 days after V0; MR2=2nd visit (6 weeks after MR1 +/- 1 week); MR3=end of study visit 12 weeks after MR1. This outcome was only measured on patients in the group "Interferon beta-1b, FRP within 15 days after randomization".	At MR2 visit (6 weeks after MR1 visit) and MR3 visit (12 weeks after MR1 visit)	No
Secondary	Knee Isokinetic Gain Between Baseline and 12 Weeks After MR1 Visit	The isokinetic evaluation analyses the flexor/extensor ratio at different rates. The evaluation will be done at the beginning on the best clinical side otherwise on the strongest. Participants had the following two types of visit during the study, one visit with a neurologist and one visit with a rehabilitation physician. Visit to a neurologist: V0=baseline; V1=end of Month 1 of treatment; V2=end of Month 2 of treatment; V3=end of Month 3 of treatment. Visit to MR (Medecin Reeducateur: physician for rehabilitation): MR1=1st visit within 15 days after V0; MR2=2nd visit (6 weeks after MR1 +/- 1 week); MR3=end of study visit 12 weeks after MR1.	At baseline and 12 weeks after MR1 visit	No
Secondary	Posturography Gain in Static Equilibrium Performances Between Baseline and 12 Weeks After MR1 Visit	Posturography protocol: Static equilibrium performances are evaluated in the standing patient on a fixed platform, in the standardized position (arms dangling, feet open at 30° and malleolus at a 5 cm distance). Participants had the following two types of visit during the study, one visit with a neurologist and one visit with a rehabilitation physician. Visit to a neurologist: V0=baseline; V1=end of Month 1 of treatment; V2=end of Month 2 of treatment; V3=end of Month 3 of treatment. Visit to MR (Medecin Reeducateur: physician for rehabilitation): MR1=1st visit within 15 days after V0; MR2=2nd visit (6 weeks after MR1 +/- 1 week); MR3=end of study visit 12 weeks after MR1.	At baseline and 12 weeks after MR1 visit	No
Secondary	Posturography Gain in Static Equilibrium Performances Between MR2 and MR3 Visits	Posturography protocol: Static equilibrium performances are evaluated in the standing patient on a fixed platform, in the standardized position (arms dangling, feet open at 30° and malleolus at a 5 cm distance). Participants had the following two types of visit during the study, one visit with a neurologist and one visit with a rehabilitation physician. Visit to a neurologist: V0=baseline; V1=end of Month 1 of treatment; V2=end of Month 2 of treatment; V3=end of Month 3 of treatment. Visit to MR (Medecin Reeducateur: physician for rehabilitation): MR1=1st visit within 15 days after V0; MR2=2nd visit (6 weeks after MR1 +/- 1 week); MR3=end of study visit 12 weeks after MR1. This outcome was only measured on patients in the group "Interferon beta-1b, FRP within 15 days after randomization".	At MR2 visit (6 weeks after MR1 visit) and MR3 visit (12 weeks after MR1 visit)	No
Secondary	Number of Participants With Fatigue Based on Participants Self Assessment Using the Fatigue Severity Scale (FSS)	FSS is an auto-questionnaire estimating the fatigue. It includes 9 questions on 7 points as well as an analogical visual scale estimating the state of fatigue over the last two weeks. Participants had the following two types of visit during the study, one visit with a neurologist and one visit with a rehabilitation physician. Visit to a neurologist: V0=baseline; V1=end of Month 1 of treatment; V2=end of Month 2 of treatment; V3=end of Month 3 of treatment. Visit to MR (Medecin Reeducateur: physician for rehabilitation): MR1=1st visit within 15 days after V0; MR2=2nd visit (6 weeks after MR1 +/- 1 week); MR3=end of study visit 12 weeks after MR1.	From baseline to 12 weeks after MR1 visit	No
Secondary	Quality of Life Assessed by Use of Self-questionnaire (SEP-59)	SEP (Sclérose en plaques) - 59: auto-questionnaire, multidimensional investigating the felt health. It contains a generic part SF (Short Form) 36 constituted by 36 items including the main concepts of quality of life and a specific part to the MS which investigates the dimensions susceptible to be degraded. 59 items are grouped in 16 dimensions: physical activity, limitations bound connected to the physical health, to the mental health, the social well-being, the pain, the energy, the emotional well-being, general Health, distress, cognitive function sexual function/satisfaction, well-being general, sleep and social support. Visit to a neurologist: V0=baseline; V1=end of Month 1 of treatment; V2=end of Month 2 of treatment; V3=end of Month 3 of treatment. Visit to MR (Medecin Reeducateur: physician for rehabilitation): MR1=1st visit within 15 days after V0; MR2=2nd visit (6 weeks after MR1 +/- 1 week); MR3=end of study visit 12 weeks after MR1.	From baseline to 12 weeks after MR1 visit	No

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.